Stock AIMT AIMMUNE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Aimmune Therapeutics, Inc.

Equities

AIMT

US00900T1079

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Aimmune Therapeutics, Inc. to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIA« [Peanut (Arachis Hypogaea) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years
CI
Allergy Partners Announces Strategic Collaboration with Aimmune Therapeutics, Inc. to Provide PALFORZIA® Directly to Patients
CI
Aimmune Therapeutics, Inc. Announces Publication of Pooled Safety Analysis of PALFORZIA® Treatment for Up to 2 Years in the Journal of Allergy and Clinical Immunology
CI
Aimmune Therapeutics, Inc. Presents New PALFORZIA?
CI
Aimmune Therapeutics Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis
CI
Aimmune Therapeutics Announces New Clinical Data from A Pooled Analysis of Three Controlled Phase 3
CI
Aimmune Therapeutics : European Commission approves Aimmune's PALFORZIA as first-ever treatment for peanut allergy in the EU
AQ
Aimmune Therapeutics : European Commission approves first treatment for peanut allergy
AQ
Aimmune Therapeutics : European Commission approves Aimmune's PALFORZIA as first-ever treatment for peanut allergy in the EU
AQ
Aimmune Therapeutics : European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU
BU
European Commission Approves Aimmune’S Palforzia as First-Ever Treatment for Peanut Allergy in the EU
CI
Nestle S A : shrugs off COVID-19 impact thanks to pet food and health nutrition
RE
AIMMUNE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers (form 8-K)
AQ
Aimmune Therapeutics, Inc. Announces Executive Changes
CI
Aimmune Therapeutics : Receives Positive CHMP Opinion on PALFORZIA for the Treatment of Patients with Peanut Allergy in Europe
AQ
Aimmune Therapeutics, Inc. Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe
CI
Aimmune Therapeutics : Nestle Completes Acquisition of Aimmune Therapeutics
AQ
Aimmune Therapeutics, Inc. Appoints Andrew Oxtoby as President
CI
Aimmune Therapeutics, Inc. Appoints Andrew Oxtoby as CEO
CI
Aimmune Therapeutics : Nestle announces results of tender offer for Aimmune Therapeutics Inc.
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AIMT Stock
  4. News Aimmune Therapeutics, Inc.